NAD + Intermediates: The Biology and Therapeutic Potential of NMN and NR

Cell Metabolism

Volumn 27, Issue 3, 2018, Pages 513-528

  Yoshino, Jun ^a   Baur, Joseph A ^b   Imai, Shin ichiro ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

Author keywords

aging; metabolism; NAD +; NAMPT; nicotinamide adenine dinucleotide; nicotinamide mononucleotide; nicotinamide phosphoribosyltransferase; nicotinamide riboside; NMN; NMN adenylyltransferases; NMNATs; NR; NR kinases; NRKs; PARPs; poly ADP ribose polymerases; sirtuins

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE RIBOSIDE; NICOTINAMIDE; NICOTINAMIDE-BETA-RIBOSIDE;

HUMAN; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REVIEW; AGING; ANALOGS AND DERIVATIVES; ANIMAL; METABOLISM;

AGING; ANIMALS; HUMANS; NAD; NIACINAMIDE; NICOTINAMIDE MONONUCLEOTIDE;

EID: 85039416228     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2017.11.002     Document Type: Review

References (125)

1. Avalos, J.L., Bever, K.M., Wolberger, C., Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol. Cell 17 (2005), 855–868.
2. Bai, P., Canto, C., Brunyanszki, A., Huber, A., Szanto, M., Cen, Y., Yamamoto, H., Houten, S.M., Kiss, B., Oudart, H., et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab. 13 (2011), 450–460.
3. Bai, P., Canto, C., Oudart, H., Brunyanszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R.H., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13 (2011), 461–468.
4. + metabolism in health and disease. Trends Biochem. Sci. 32 (2007), 12–19.
5. Berger, F., Ramirez-Hernandez, M.H., Ziegler, M., The new life of a centenarian: signalling functions of NAD(P). Trends Biochem. Sci. 29 (2004), 111–118.
6. + in fungi and humans. Cell 117 (2004), 495–502.
7. Bitterman, K.J., Anderson, R.M., Cohen, H.Y., Latorre-Esteves, M., Sinclair, D.A., Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277 (2002), 45099–45107.
8. + metabolism oxidative stress and Sirt1 activity in Wistar rats. PLoS One, 6, 2011, e19194.
9. Brown, K.D., Maqsood, S., Huang, J.Y., Pan, Y., Harkcom, W., Li, W., Sauve, A., Verdin, E., Jaffrey, S.R., Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 20 (2014), 1059–1068.
10. Camacho-Pereira, J., Tarrago, M.G., Chini, C.C., Nin, V., Escande, C., Warner, G.M., Puranik, A.S., Schoon, R.A., Reid, J.M., Galina, A., et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23 (2016), 1127–1139.
11. Canto, C., Houtkooper, R.H., Pirinen, E., Youn, D.Y., Oosterveer, M.H., Cen, Y., Fernandez-Marcos, P.J., Yamamoto, H., Andreux, P.A., Cettour-Rose, P., et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15 (2012), 838–847.
12. Canto, C., Menzies, K.J., Auwerx, J., NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22 (2015), 31–53.
13. Caton, P.W., Kieswich, J., Yaqoob, M.M., Holness, M.J., Sugden, M.C., Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia 54 (2011), 3083–3092.
14. Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A.A., Li, W., Leoni, V., Schon, E.A., Dantzer, F., Auwerx, J., et al. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab. 19 (2014), 1042–1049.
15. Chalkiadaki, A., Guarente, L., The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer 15 (2015), 608–624.
16. Chalkiadaki, A., Igarashi, M., Nasamu, A.S., Knezevic, J., Guarente, L., Muscle-specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates pathophysiology in a mouse model of Duchenne muscular dystrophy. PLoS Genet., 10, 2014, e1004490.
17. Chambon, P., Weill, J.D., Mandel, P., Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 11 (1963), 39–43.
18. Chini, C.C., Tarrago, M.G., Chini, E.N., NAD and the aging process: role in life, death and everything in between. Mol. Cell Endocrinol. 455 (2016), 62–74.
19. + levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 12 (2013), 1062–1072.
20. Conze, D.B., Crespo-Barreto, J., Kruger, C.L., Safety assessment of nicotinamide riboside, a form of vitamin B3. Hum. Exp. Toxicol., 2016, 10.1177/0960327115626254.
21. de Picciotto, N.E., Gano, L.B., Johnson, L.C., Martens, C.R., Sindler, A.L., Mills, K.F., Imai, S., Seals, D.R., Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell 15 (2016), 522–530.
22. DeFronzo, R.A., Ferrannini, E., Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991), 173–194.
23. Di Stefano, M., Nascimento-Ferreira, I., Orsomando, G., Mori, V., Gilley, J., Brown, R., Janeckova, L., Vargas, M.E., Worrell, L.A., Loreto, A., et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ. 22 (2015), 731–742.
24. Dietrich, L.S., Muniz, O., Powanda, M., NAD synthesis in animal tissues. J. Vitaminol. (Kyoto) 14:Suppl (1968), 123–129.
25. Elvehjem, C.A., Pellagra, a deficiency disease. Proc. Am. Philos. Soc. 93 (1949), 335–339.
26. Escande, C., Chini, C.C., Nin, V., Dykhouse, K.M., Novak, C.M., Levine, J., van Deursen, J., Gores, G.J., Chen, J., Lou, Z., et al. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J. Clin. Invest. 120 (2010), 545–558.
27. + replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24 (2016), 566–581.
28. + in aging: molecular mechanisms and translational implications. Trends Mol. Med. 23 (2017), 899–916.
29. Fang, E.F., Scheibye-Knudsen, M., Brace, L.E., Kassahun, H., SenGupta, T., Nilsen, H., Mitchell, J.R., Croteau, D.L., Bohr, V.A., Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 157 (2014), 882–896.
30. Fletcher, R.S., Ratajczak, J., Doig, C.L., Oakey, L.A., Callingham, R., Da Silva Xavier, G., Garten, A., Elhassan, Y.S., Redpath, P., Migaud, M.E., et al. Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells. Mol. Metab. 6 (2017), 819–832.
31. Frederick, D.W., Davis, J.G., Davila, A. Jr., Agarwal, B., Michan, S., Puchowicz, M.A., Nakamaru-Ogiso, E., Baur, J.A., Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism. J. Biol. Chem. 290 (2015), 1546–1558.
32. Frederick, D.W., Loro, E., Liu, L., Davila, A. Jr., Chellappa, K., Silverman, I.M., Quinn, W.J. 3rd, Gosai, S.J., Tichy, E.D., Davis, J.G., et al. Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle. Cell Metab. 24 (2016), 269–282.
33. Friebe, D., Neef, M., Kratzsch, J., Erbs, S., Dittrich, K., Garten, A., Petzold-Quinque, S., Bluher, S., Reinehr, T., Stumvoll, M., et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 54 (2011), 1200–1211.
34. Gariani, K., Menzies, K.J., Ryu, D., Wegner, C.J., Wang, X., Ropelle, E.R., Moullan, N., Zhang, H., Perino, A., Lemos, V., et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 63 (2016), 1190–1204.
35. Garten, A., Schuster, S., Penke, M., Gorski, T., de Giorgis, T., Kiess, W., Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat. Rev. Endocrinol. 11 (2015), 535–546.
36. + metabolism. Neuron 89 (2016), 449–460.
37. Gholson, R.K., The pyridine nucleotide cycle. Nature 212 (1966), 933–935.
38. Gomes, A.L., Teijeiro, A., Buren, S., Tummala, K.S., Yilmaz, M., Waisman, A., Theurillat, J.P., Perna, C., Djouder, N., Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30 (2016), 161–175.
39. Gomes, A.P., Price, N.L., Ling, A.J., Moslehi, J.J., Montgomery, M.K., Rajman, L., White, J.P., Teodoro, J.S., Wrann, C.D., Hubbard, B.P., et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155 (2013), 1624–1638.
40. Gong, B., Pan, Y., Vempati, P., Zhao, W., Knable, L., Ho, L., Wang, J., Sastre, M., Ono, K., Sauve, A.A., et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging 34 (2013), 1581–1588.
41. + biosynthesis in FK866-treated tumor cells. J. Biol. Chem. 288 (2013), 25938–25949.
42. + precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner. J. Am. Soc. Nephrol. 28 (2017), 2337–2352.
43. Guest, J., Grant, R., Mori, T.A., Croft, K.D., Changes in oxidative damage, inflammation and [NAD(H)] with age in cerebrospinal fluid. PLoS One, 9, 2014, e85335.
44. + -dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc. Natl. Acad. Sci. USA 113 (2016), E8247–E8256.
45. Hallschmid, M., Randeva, H., Tan, B.K., Kern, W., Lehnert, H., Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes 58 (2009), 637–640.
46. + precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Pain 158 (2017), 962–972.
47. Hara, N., Yamada, K., Shibata, T., Osago, H., Tsuchiya, M., Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS One, 6, 2011, e22781.
48. Harden, A., Young, W.J., The alcoholic ferment of yeast-juice. Part II.–The conferment of yeast-juice. Proc. R. Soc. Lond. 78 (1906), 369–375.
49. Ikeda, M., Tsuji, H., Nakamura, S., Ichiyama, A., Nishizuka, Y., Hayaishi, O., Studies on the biosynthesis of nicotinamide adenine dinucleotide. II. A role of picolinic carboxylase in the biosynthesis of nicotinamide adenine dinucleotide from tryptophan in mammals. J. Biol. Chem. 240 (1965), 1395–1401.
50. Imai, S., From heterochromatin islands to the NAD World: a hierarchical view of aging through the functions of mammalian Sirt1 and systemic NAD biosynthesis. Biochim. Biophys. Acta 1790 (2009), 997–1004.
51. Imai, S., The NAD World: a new systemic regulatory network for metabolism and aging–Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem. Biophys. 53 (2009), 65–74.
52. Imai, S., “Clocks” in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim. Biophys. Acta 1804 (2010), 1584–1590.
53. Imai, S., Armstrong, C.M., Kaeberlein, M., Guarente, L., Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403 (2000), 795–800.
54. + and sirtuins in aging and disease. Trends Cell Biol. 24 (2014), 464–471.
55. Imai, S., Yoshino, J., The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes. Metab. 15:Suppl 3 (2013), 26–33.
56. + /SIRT1 in mammalian aging and longevity control. NPJ Syst. Biol. Appl., 2, 2016, 16018.
57. Karamanlidis, G., Lee, C.F., Garcia-Menendez, L., Kolwicz, S.C. Jr., Suthammarak, W., Gong, G., Sedensky, M.M., Morgan, P.G., Wang, W., Tian, R., Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 18 (2013), 239–250.
58. + metabolism, from bench to bedside. EMBO J. 36 (2017), 2670–2683.
59. Kawamura, T., Mori, N., Shibata, K., beta-nicotinamide mononucleotide, an anti-aging candidate compound, is retained in the body for longer than nicotinamide in rats. J. Nutr. Sci. Vitaminol. (Tokyo) 62 (2016), 272–276.
60. Khan, N.A., Auranen, M., Paetau, I., Pirinen, E., Euro, L., Forsstrom, S., Pasila, L., Velagapudi, V., Carroll, C.J., Auwerx, J., et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol. Med. 6 (2014), 721–731.
61. Kieswich, J., Sayers, S.R., Silvestre, M.F., Harwood, S.M., Yaqoob, M.M., Caton, P.W., Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment. Diabetologia 59 (2016), 2477–2486.
62. Kim, M.K., Lee, J.H., Kim, H., Park, S.J., Kim, S.H., Kang, G.B., Lee, Y.S., Kim, J.B., Kim, K.K., Suh, S.W., et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J. Mol. Biol. 362 (2006), 66–77.
63. Körner, A., Garten, A., Bluher, M., Tauscher, R., Kratzsch, J., Kiess, W., Molecular characteristics of serum visfatin and differential detection by immunoassays. J. Clin. Endocrinol. Metab. 92 (2007), 4783–4791.
64. Kourtzidis, I.A., Stoupas, A.T., Gioris, I.S., Veskoukis, A.S., Margaritelis, N.V., Tsantarliotou, M., Taitzoglou, I., Vrabas, I.S., Paschalis, V., Kyparos, A., et al. The NAD(+) precursor nicotinamide riboside decreases exercise performance in rats. J. Int. Soc. Sports Nutr., 13, 2016, 32.
65. Kulikova, V., Shabalin, K., Nerinovski, K., Dolle, C., Niere, M., Yakimov, A., Redpath, P., Khodorkovskiy, M., Migaud, M.E., Ziegler, M., et al. Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells. J. Biol. Chem. 290 (2015), 27124–27137.
66. + redox balance as a therapy for heart failure. Circulation 134 (2016), 883–894.
67. + into a calcium-mobilizing metabolite. Cell Regul. 2 (1991), 203–209.
68. 2+ -mobilizing activity. J. Biol. Chem. 264 (1989), 1608–1615.
69. Lee, H.J., Hong, Y.S., Jun, W., Yang, S.J., Nicotinamide riboside ameliorates hepatic metaflammation by modulating NLRP3 inflammasome in a rodent model of type 2 diabetes. J. Med. Food 18 (2015), 1207–1213.
70. + binding pocket that regulates protein-protein interactions during aging. Science 355 (2017), 1312–1317.
71. Lin, J.B., Kubota, S., Ban, N., Yoshida, M., Santeford, A., Sene, A., Nakamura, R., Zapata, N., Kubota, M., Tsubota, K., et al. NAMPT-mediated NAD(+) biosynthesis is essential for vision in mice. Cell Rep. 17 (2016), 69–85.
72. Long, A.N., Owens, K., Schlappal, A.E., Kristian, T., Fishman, P.S., Schuh, R.A., Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model. BMC Neurol., 15, 2015, 19.
73. Martin, A.S., Abraham, D.M., Hershberger, K.A., Bhatt, D.P., Mao, L., Cui, H., Liu, J., Liu, X., Muehlbauer, M.J., Grimsrud, P.A., et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model. JCI Insight, 2, 2017, 10.1172/jci.insight.93885.
74. + metabolism in human tissue. PLoS One, 7, 2012, e42357.
75. Mills, K.F., Yoshida, S., Stein, L.R., Grozio, A., Kubota, S., Sasaki, Y., Redpath, P., Migaud, M.E., Apte, R.S., Uchida, K., et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 24 (2016), 795–806.
76. Mouchiroud, L., Houtkooper, R.H., Moullan, N., Katsyuba, E., Ryu, D., Canto, C., Mottis, A., Jo, Y.S., Viswanathan, M., Schoonjans, K., et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154 (2013), 430–441.
77. Mukherjee, S., Chellappa, K., Moffitt, A., Ndungu, J., Dellinger, R.W., Davis, J.G., Agarwal, B., Baur, J.A., Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration. Hepatology 65 (2017), 616–630.
78. + salvage pathway by CLOCK-SIRT1. Science 324 (2009), 654–657.
79. Nikiforov, A., Dolle, C., Niere, M., Ziegler, M., Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J. Biol. Chem. 286 (2011), 21767–21778.
80. North, B.J., Rosenberg, M.A., Jeganathan, K.B., Hafner, A.V., Michan, S., Dai, J., Baker, D.J., Cen, Y., Wu, L.E., Sauve, A.A., et al. SIRT2 induces the checkpoint kinase BubR1 to increase lifespan. EMBO J. 33 (2014), 1438–1453.
81. Park, J.H., Long, A., Owens, K., Kristian, T., Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia. Neurobiol. Dis. 95 (2016), 102–110.
82. + cycle drives mitochondrial oxidative metabolism in mice. Science, 342, 2013, 1243417.
83. Pillai, V.B., Sundaresan, N.R., Kim, G., Samant, S., Moreno-Vinasco, L., Garcia, J.G., Gupta, M.P., Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol. 304 (2013), H415–H426.
84. Ramsey, K.M., Mills, K.F., Satoh, A., Imai, S., Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7 (2008), 78–88.
85. + biosynthesis. Science 324 (2009), 651–654.
86. Ratajczak, J., Joffraud, M., Trammell, S.A., Ras, R., Canela, N., Boutant, M., Kulkarni, S.S., Rodrigues, M., Redpath, P., Migaud, M.E., et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat. Commun., 7, 2016, 13103.
87. Reaven, G.M., Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988), 1595–1607.
88. Rechsteiner, M., Hillyard, D., Olivera, B.M., Magnitude and significance of NAD turnover in human cell line D98/AH2. Nature 259 (1976), 695–696.
89. Revollo, J.R., Grimm, A.A., Imai, S., The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279 (2004), 50754–50763.
90. Revollo, J.R., Korner, A., Mills, K.F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R.R., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6 (2007), 363–375.
91. Riammer, S., Garten, A., Schaab, M., Grunewald, S., Kiess, W., Kratzsch, J., Paasch, U., Nicotinamide phosphoribosyltransferase production in human spermatozoa is influenced by maturation stage. Andrology 4 (2016), 1045–1053.
92. Rongvaux, A., Shea, R.J., Mulks, M.H., Gigot, D., Urbain, J., Leo, O., Andris, F., Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32 (2002), 3225–3234.
93. Rowen, J.W., Kornberg, A., The phosphorolysis of nicotinamide riboside. J. Biol. Chem. 193 (1951), 497–507.
94. + repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci. Transl. Med., 8, 2016, 361ra139.
95. Scheibye-Knudsen, M., Mitchell, S.J., Fang, E.F., Iyama, T., Ward, T., Wang, J., Dunn, C.A., Singh, N., Veith, S., Hasan-Olive, M.M., et al. A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 20 (2014), 840–855.
96. Schuster, S., Penke, M., Gorski, T., Petzold-Quinque, S., Damm, G., Gebhardt, R., Kiess, W., Garten, A., Resveratrol differentially regulates NAMPT and SIRT1 in hepatocarcinoma cells and primary human hepatocytes. PLoS One, 9, 2014, e91045.
97. Schweiger, M., Hennig, K., Lerner, F., Niere, M., Hirsch-Kauffmann, M., Specht, T., Weise, C., Oei, S.L., Ziegler, M., Characterization of recombinant human nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD synthesis. FEBS Lett. 492 (2001), 95–100.
98. Shi, W., Hegeman, M.A., van Dartel, D.A.M., Tang, J., Suarez, M., Swarts, H., van der Hee, B., Arola, L., Keijer, J., Effects of a wide range of dietary nicotinamide riboside (NR) concentrations on metabolic flexibility and white adipose tissue (WAT) of mice fed a mildly obesogenic diet. Mol. Nutr. Food Res., 61, 2017, 10.1002/mnfr.201600878.
99. Sociali, G., Raffaghello, L., Magnone, M., Zamporlini, F., Emionite, L., Sturla, L., Bianchi, G., Vigliarolo, T., Nahimana, A., Nencioni, A., et al. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget 7 (2016), 2968–2984.
100. States, D.J., Walseth, T.F., Lee, H.C., Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38. Trends Biochem. Sci., 17, 1992, 495.
101. Stein, L.R., Imai, S., Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J. 33 (2014), 1321–1340.
102. Stromsdorfer, K.L., Yamaguchi, S., Yoon, M.J., Moseley, A.C., Franczyk, M.P., Kelly, S.C., Qi, N., Imai, S., Yoshino, J., NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 16 (2016), 1851–1860.
103. Trammell, S.A., Schmidt, M.S., Weidemann, B.J., Redpath, P., Jaksch, F., Dellinger, R.W., Li, Z., Abel, E.D., Migaud, M.E., Brenner, C., Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun., 7, 2016, 12948.
104. Trammell, S.A., Weidemann, B.J., Chadda, A., Yorek, M.S., Holmes, A., Coppey, L.J., Obrosov, A., Kardon, R.H., Yorek, M.A., Brenner, C., Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci. Rep., 6, 2016, 26933.
105. Tummala, K.S., Gomes, A.L., Yilmaz, M., Grana, O., Bakiri, L., Ruppen, I., Ximenez-Embun, P., Sheshappanavar, V., Rodriguez-Justo, M., Pisano, D.G., et al. Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. Cancer Cell 26 (2014), 826–839.
106. Uddin, G.M., Youngson, N.A., Sinclair, D.A., Morris, M.J., Head to head comparison of short-term treatment with the NAD(+) precursor nicotinamide mononucleotide (NMN) and 6 weeks of exercise in obese female mice. Front. Pharmacol., 7, 2016, 258.
107. Ummarino, S., Mozzon, M., Zamporlini, F., Amici, A., Mazzola, F., Orsomando, G., Ruggieri, S., Raffaelli, N., Simultaneous quantitation of nicotinamide riboside, nicotinamide mononucleotide and nicotinamide adenine dinucleotide in milk by a novel enzyme-coupled assay. Food Chem. 221 (2017), 161–168.
108. Verdin, E., NAD(+) in aging, metabolism, and neurodegeneration. Science 350 (2015), 1208–1213.
109. Wang, T., Zhang, X., Bheda, P., Revollo, J.R., Imai, S., Wolberger, C., Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol. 13 (2006), 661–662.
110. Wang, X., Hu, X., Yang, Y., Takata, T., Sakurai, T., Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 1643 (2016), 1–9.
111. Wang, X., Zhang, Z.F., Zheng, G.H., Wang, A.M., Sun, C.H., Qin, S.P., Zhuang, J., Lu, J., Ma, D.F., Zheng, Y.L., The inhibitory effects of purple sweet potato color on hepatic inflammation is associated with restoration of NAD(+) levels and attenuation of NLRP3 inflammasome activation in high-fat-diet-treated mice. Molecules, 22, 2017, 10.3390/molecules22081315.
112. Wei, C.C., Kong, Y.Y., Li, G.Q., Guan, Y.F., Wang, P., Miao, C.Y., Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci. Rep., 7, 2017, 717.
113. Wei, C.C., Kong, Y.Y., Xia, H., Li, G.Q., Zheng, S.L., Cheng, M.H., Wang, P., Miao, C.Y., NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tPA-induced haemorrhagic transformation after cerebral ischemia. Br. J. Pharmacol. 174 (2017), 3823–3836.
114. Xu, W., Barrientos, T., Mao, L., Rockman, H.A., Sauve, A.A., Andrews, N.C., Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep. 13 (2015), 533–545.
115. Yamaguchi, S., Yoshino, J., Adipose tissue NAD+ biology in obesity and insulin resistance: from mechanism to therapy. Bioessays, 39, 2017, 10.1002/bies.201600227.
116. + synthesis, protects the heart from ischemia and reperfusion. PLoS One, 9, 2014, e98972.
117. Yang, Y., Sauve, A.A., NAD+ metabolism: bioenergetics, signaling and manipulation for therapy. Biochim. Biophys. Acta 1864 (2016), 1787–1800.
118. Yano, M., Akazawa, H., Oka, T., Yabumoto, C., Kudo-Sakamoto, Y., Kamo, T., Shimizu, Y., Yagi, H., Naito, A.T., Lee, J.K., et al. Monocyte-derived extracellular Nampt-dependent biosynthesis of NAD(+) protects the heart against pressure overload. Sci. Rep., 5, 2015, 15857.
119. Yao, Z., Yang, W., Gao, Z., Jia, P., Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci. Lett. 647 (2017), 133–140.
120. Yoon, M.J., Yoshida, M., Johnson, S., Takikawa, A., Usui, I., Tobe, K., Nakagawa, T., Yoshino, J., Imai, S., SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD(+) and function in mice. Cell Metab. 21 (2015), 706–717.
121. Yoshino, J., Mills, K.F., Yoon, M.J., Imai, S., Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14 (2011), 528–536.
122. Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D'Amico, D., Ropelle, E.R., Lutolf, M.P., Aebersold, R., et al. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352 (2016), 1436–1443.
123. Zhao, Y., Liu, X.Z., Tian, W.W., Guan, Y.F., Wang, P., Miao, C.Y., Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury. CNS Neurosci. Ther. 20 (2014), 539–547.
124. Zhou, C.C., Yang, X., Hua, X., Liu, J., Fan, M.B., Li, G.Q., Song, J., Xu, T.Y., Li, Z.Y., Guan, Y.F., et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br. J. Pharmacol. 173 (2016), 2352–2368.
125. Zhu, X.H., Lu, M., Lee, B.Y., Ugurbil, K., Chen, W., In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. Natl. Acad. Sci. USA 112 (2015), 2876–2881.